MAP2K7 and myxofibrosarcoma: A case report of a patient with advanced chemotherapy-refractory myxofibrosarcoma harboring RAF1 S259P mutation and CDKN2A/B loss showed complete radiological response on treatment with MEK inhibitor Trametinib and CDK4/6 inhibitor Palbocilib.